NAPL Napo Pharm.Regs

Napo Pharmaceuticals Inc
04 February 2008


For immediate release                                            4 February 2008

                           Napo Pharmaceuticals, Inc.

           Napo Appoints Dr. Jerome Ernst as Clinical Science Advisor

South San Francisco, California, Napo Pharmaceuticals, Inc., 4 February 2008
(LSE: NAPL), which focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners, announces the appointment of Jerome Ernst, M.D., M.S. as
Clinical Science Advisor.  Dr. Ernst joins the Clinical Development team at Napo
and will assume certain of the strategic and operational responsibilities for
the CRO-HIV Phase 3 trial for crofelemer.   Dr. M. Scott Harris will remain the
Medical Monitor for Napo's ongoing crofelemer clinical trials in a consulting
role.

Dr. Ernst is a board certified physician in internal medicine and pulmonary
diseases.  Since 1999, Dr. Ernst has been the Medical Director of the AIDS
Community Research Initiative of America (ACRIA), a New York-based non-profit
research organization engaged in AIDS-related research.  Since 2000, Dr. Ernst
has also been the Medical Director of VidaCare, a non-profit special needs
program (SNP) of New York Medicaid Managed Care for people living with HIV and
AIDS.  Prior to his appointments with ACRIA and VidaCare, Dr. Ernst created and
led the AIDS Program at the Bronx-Lebanon Hospital Center from the start of the
epidemic through 1999.  He also served as the Associate Director of Medicine and
Chief of Pulmonary Diseases and Critical Care, as well as the first Chief of
Infectious Diseases, during his tenure at the Bronx-Lebanon Hospital Center.
Currently, Dr. Ernst is also an Associate Professor of Medicine at the Albert
Einstein College of Medicine, where he has remained on their faculty since 1988,
holding faculty positions in Medicine, Epidemiology and Social Medicine.  Dr.
Ernst is also the Vice-Chairman of the Board of Directors for the Bronx AIDS
Services and previously held Board positions at the Bronx-Lebanon Hospital
Center and the Highbridge Woodycrest Center.  Dr. Ernst obtained his degree in
medicine cum laude from Tel Aviv University.  He also holds a master's degree in
public administration from New York University.  Dr. Ernst has approximately 30
publications and book chapters and has made more than 35 presentations at
national and international research meetings.  He is a member of several
prestigious professional societies and has been a recipient of numerous research
grants.  He has also been an investigator on several HIV/AIDS clinical trials.

Lisa A. Conte, CEO of Napo commented:  "We are very happy that Dr. Ernst has
accepted this position and joins the Napo team.  He is very familiar with
crofelemer and quite importantly, clinical trials involving the HIV/AIDS
community and understands the challenges chronic diarrhoea causes to people
living with HIV/AIDS."

Dr. Ernst commented:  "My interest in Napo comes from its incorporation of
global health issues and solutions into its business strategy.  Crofelemer, once
approved, will be an important product that will address both diarrhoea and
dehydration, not only in people living with HIV/AIDS, but also in
life-threatening situations around the globe."

For more information please contact:
Napo Pharmaceuticals, Inc.                            (001) + 650 616 1902
Lisa Conte, Chief Executive Officer
Charles Thompson, Chief Financial Officer             (001) + 650 616 1903

Buchanan Communications                               020 7466 5000
Tim Anderson, Mary-Jane Johnson

Nomura Code Securities Limited                        020 7776 1205
Clare Terlouw

About Napo Pharmaceuticals, Inc.

Napo Pharmaceuticals, Inc. focuses on the development and commercialisation of
proprietary pharmaceuticals for the global marketplace in collaboration with
local partners. Napo was founded in November 2001, and is based in California,
USA with a subsidiary in Mumbai, India.

Napo's late-stage proprietary gastro-intestinal compound, crofelemer, is in
various stages of clinical development for four distinct product indications,
including a late-stage Phase 3 program:

  * CRO-HIV for AIDS diarrhea, Phase 3
  * CRO-IBS for diarrhea irritable bowel syndrome ("D-IBS"), Phase 2
  * CRO-ID for acute infectious diarrhea (including cholera), Phase 2
  * CRO-PED for paediatric diarrhea, Phase 1

The FDA has granted fast-track status to CRO-IBS and CRO-HIV.

Crofelemer, a proprietary patented agent, is extracted from Croton lechleri, a
medicinal plant which can be sustainably harvested from several countries in
South America. Napo also plans to develop an early clinical stage product,
NP-500, for the treatment of insulin resistant diseases of Type II diabetes and
metabolic syndrome (Syndrome X; pre-diabetic syndrome). Napo also has a plant
library of approximately 2,300 medicinal plants from tropical regions, and Napo
has entered two screening relationship associated with this collection.
Currently, products are based on the chemical and biological diversity derived
from plants with medicinal properties, but future products may be in-licensed
from other sources.

Napo has partnerships with Trine Pharmaceuticals, Inc. of the United States of
America; Glenmark Pharmaceuticals Limited of India; and AsiaPharm Group Ltd. of
China. For more information please visit www.napopharma.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRADBGDDXGGGGIX

Napo Pharm.Regs (LSE:NAPL)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Napo Pharm.Regs (LSE:NAPL)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024